The Belgian-Dutch company Allero Therapeutics BV has appointed Steven Glazer as chief medical officer and Christophe Saillez as vice president for regulatory affairs. Allero is building a pipeline of products for food-related immune disorders leveraging the properties of the oral immune system. Dr Glazer joins from the Danish immuno-oncology company Monta BioSciences ApS where he was chief medical officer. Before that, he was medical director at RhoVac AB and chair of the scientific board of Immunicum AB. He obtained his medical degree from the University of Copenhagen, Denmark.
Mr Saillez is a regulatory and scientific expert who has held management positions at Actobio Therapeutics Inc and GlaxoSmithKline Vaccines.
Allero Therapeutics announced the appointments on 15 December 2020.
Copyright 2020 Evernow Publishing Ltd